Novel approaches in the treatment of myositis and myopathies

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 5, 2012, Pages 369-377

  Albayda, Jemima ^a   Christopher Stine, Lisa ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

gene therapy; idiopathic inflammatory myopathies; IVIG; novel approaches; rituximab; stem cell transplantation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; CALPEPTIN; CORTICOSTEROID; ETANERCEPT; FOLLISTATIN; IMMUNOGLOBULIN; METHOTREXATE; MIZORIBINE; MYOSTATIN; PLACEBO; PREDNISONE; RECEPTOR INTERACTING PROTEIN 140; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOID; RITUXIMAB; SIFALIMUMAB; SIMVASTATIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD VESSEL OCCLUSION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DERMATOMYOSITIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; EXERCISE; GENE THERAPY; HUMAN; IMMUNOPATHOGENESIS; INCLUSION BODY MYOSITIS; JUVENILE DERMATOMYOSITIS; LOW DRUG DOSE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR MODEL; MYOPATHY; MYOSITIS; NONHUMAN; OUTCOME ASSESSMENT; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 84869821461     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12447705     Document Type: Review

References (56)

1. Bakewell C.J. Raghu G. (2011) Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139: 441–443.
2. Couderc M. Gottenberg J.E. Mariette X. Hachulla E. Sibilia J. Fain O. et al. (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford, England) 50: 2283–2289.
3. Crescioli C. Sottili M. Bonini P. Cosmi L. Chiarugi P. Romagnani P. et al. (2011) Inflammatory response in human skeletal muscle cells: CXCL 10 as a potential therapeutic target. Eur J Cell Biol 91: 139–149.
4. Dalakas M.C. Rakocevic G. Schmidt J. Salajegheh M. McElroy B. Harris-Love M.O. et al. (2009) Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132: 1536–1544.
5. Danieli M.G. Pettinari L. Moretti R. Logullo F. Gabrielli A. (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10: 144–149.
6. Diot E. Carmier D. Marquette D. Marchand-Adam S. Diot P. Lesire V. (2011) IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 140: 562–563.
7. Donofrio P.D. Berger A. Brannagan T.H. III Bromberg M.B. Howard J.F. Latov N. et al. (2009) Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40: 890–900.
8. Dorph C. Dastmalchi M. Alexanderson H. Ottosson C. Lindroos E. Nennesmo I. et al. (2009) Anakinra in patients with refractory idiopathic inflammatory myopathies. Arthritis Rheum 60(Suppl. 10): 589.
9. Frikha F. Rigolet A. Behin A. Fautrel B. Herson S. Benveniste O. (2009) Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology (Oxford, England) 48: 1166–1168.
10. Greenberg S.A. (2010 a) Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 12: 198–203.
11. Greenberg S.A. (2010 b) Type 1 interferons and myositis. Arthritis Res Ther 12(Suppl. 1): S4.
12. Gualano B. Neves M. Jr Lima F.R. Pinto A.L. Laurentino G. Borges C. et al. (2010 a) Resistance training with vascular occlusion in inclusion body myositis: a case study. Med Sci Sports Exercise 42: 250–254.
13. Gualano B. Ugrinowitsch C. Neves M. Jr Lima F.R. Pinto A.L. Laurentino G. et al. (2010 b) Vascular occlusion training for inclusion body myositis: a novel therapeutic approach. J Visual Exp 40: 1894, DOI: 10.3791/1894.
14. Haidet A.M. Rizo L. Handy C. Umapathi P. Eagle A. Shilling C. et al. (2008) Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 105: 4318–4322.
15. Hak A. de Paepe B. de Bleecker J. Tak P. de Visser M. (2011) Dermatomyositis and polymyositis: new treatment targets on the horizon. Netherlands J Med 69: 410–421.
16. Haroon M. Devlin J. (2010) Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int: 1-2.
17. Hartung H.P. Mouthon L. Ahmed R. Jordan S. Laupland K.B. Jolles S. (2009) Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol 158(Suppl. 1): 23–33.
18. Henes J.C. Heinzelmann F. Wacker A. Seelig H.P. Klein R. Bornemann A. et al. (2009) Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation. Ann Rheum Dis 68: 447–448.
19. Holzer U. van Royen-Kerkhof A. van der Torre P. Kuemmerle-Deschner J. Well C. Handgretinger N. et al. (2010) Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 39: 88–92.
20. Joshi N. Nautiyal A. Davies P.G. (2011) Successful use of rituximab in recalcitrant skin predominant dermatomyositis. J Clin Rheumatol 17: 111–112.
21. Katz U. Shoenfeld Y. Zandman-Goddard G. (2011) Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharmaceut Des 17: 3166–3175.
22. Kota J. Handy C.R. Haidet A.M. Montgomery C.L. Eagle A. Rodino-Klapac L.R. et al. (2009) Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Translational Med 1 (6): 6ra15.
23. Levesque M.C. (2009) Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 157: 198-208.
24. Levy D.M. Bingham C.A. Kahn P.J. Eichenfield A.H. Imundo L.F. (2010) Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatrics 156: 302–307.
25. Linardaki G. Cherouvim E. Goni G. Boki K.A. (2011) Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis. Rheumatol Int 31: 113–115.
26. Lundberg I.E. Helmers S.B. (2010) The type I interferon system in idiopathic inflammatory myopathies. Autoimmunity 43: 239–243.
27. Mahler E.A. Blom M. Voermans N.C. van Engelen B.G. van Riel P.L. Vonk M.C. (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford, England) 50: 2206–2213.
28. Majmudar S. Hall H.A. Zimmermann B. (2009) Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 15: 338–340.
29. Marie I. Menard J.F. Hatron P.Y. Hachulla E. Mouthon L. Tiev K. et al. (2010) Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res 62: 1748–1755.
30. Mendell J.R. Rodino-Klapac L.R. Rosales-Quintero X. Kota J. Coley B.D. Galloway G. et al. (2009) Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 66: 290–297.
31. Mendell J.R. Rodino-Klapac L.R. Rosales X.Q. Coley B.D. Galloway G. Lewis S. et al. (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68: 629–638.
32. Mishra P.J. Bertino J.R. (2009) MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10: 399–416.
33. Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70: 427–436.
34. Musuruana J.L. Cavallasca J.A. (2011) Abatacept for treatment of refractory polymyositis. Joint Bone Spine Rev Rhumatisme 78: 431–432.
35. Nader G.A. Lundberg I.E. (2009) Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol 21: 599–603.
36. Narazaki M. Hagihara K. Shima Y. Ogata A. Kishimoto T. Tanaka T. (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford, England) 50: 1344–1346.
37. Nozaki K. Das A. Ray S.K. Banik N.L. (2011) Calpeptin attenuated apoptosis and intracellular inflammatory changes in muscle cells. J Neurosci Res 89: 536–543.
38. Oddis C. Reed A. Aggarwal R. Ascherman D. Barohn R. Feldman B. et al. (2010) Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - The RIM Study. In: ACR/ARHP Scientific Meeting, Atlanta, GA, 10 November 2010.
39. Ohyanagi N. Ishido M. Suzuki F. Kaneko K. Kubota T. Miyasaka N. et al. (2009) Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo. Arthritis Rheum 60: 3118–3127.
40. Okiyama N. Sugihara T. Iwakura Y. Yokozeki H. Miyasaka N. Kohsaka H. (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60: 2505–2512.
41. Quick A. Tandan R. (2011) Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep 13: 192–198.
42. Recher M. Sahrbacher U. Bremer J. Arndt B. Steiner U. Fontana A. (2010) Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatol Int 32: 469–472.
43. Rezaei N. Abolhassani H. Aghamohammadi A. Ochs H.D. (2011) Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol 7: 301–316.
44. Rodino-Klapac L.R. Haidet A.M. Kota J. Handy C. Kaspar B.K. Mendell J.R. (2009) Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39: 283–296.
45. Sancricca C. Mora M. Ricci E. Tonali P.A. Mantegazza R. Mirabella M. (2011) Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurological Sci 32: 841–847.
46. Sem M. Molberg O. Lund M.B. Gran J.T. (2009) Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford, England) 48: 968–971.
47. Sibley C.R. Wood M.J. (2011) The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy. J Mol Med (Berlin, Germany) 89: 1065–1077.
48. Stubgen J.P. (2011) Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol 258: 961–970.
49. Suwa A. Hirakata M. Kaneko Y. Sato S. Suzuki Y. Kuwana M. (2009) Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: case report. Clin Rheumatol 28: 227–229.
50. Szodoray P. Alex P. Knowlton N. Dozmorov I. Csipo I. Nagy A.T. et al. (2010) Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford, England) 49: 1867–1877.
51. Valiyil R. Casciola-Rosen L. Hong G. Mammen A. Christopher-Stine L. (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62: 1328–1334.
52. Vandenbroucke E. Grutters J.C. Altenburg J. Boersma W.G. ter Borg E.J. van den Bosch J.M. (2009) Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 29: 1499–1502.
53. Wang D. Zhang H. Cao M. Tang Y. Liang J. Feng X. et al. (2011) Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 70: 1285–1288.
54. Whelan B.R. Isenberg D.A. (2009) Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford, England) 48: 594–595.
55. Yamamoto H. Williams E.G. Mouchiroud L. Canto C. Fan W. Downes M. et al. (2011) NCoR 1 is a conserved physiological modulator of muscle mass and oxidative function. Cell 147: 827–839.
56. Zong M. Malmstrom V. Lundberg I.E. (2011) Anakinra effects on T cells in patients with refractory idiopathic inflammatory myopathies. Ann Rheum Dis 70(Suppl. 2): 80–81.